The efficacy of azithromycin eye drops on the findings around the eyelids of patients with blepharitis

The efficacy of Azimycin 1% eye drops on the diagnosis and observation around the eyelids of patients with blepharitis - The efficacy of Azimycin 1% eye drops on the diagnosis and observation around the eyelids of patients with blepharitis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044348

Enrollment

Registered

2021-05-31

Start date

2021-06-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

blepharitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Patients who understands the contents of the consent document and is able to consent in the document of the person. 2 Age of 20 years or older. 3 Patients who were defined as bacterial blepharitis at the administration start date, and with a score of 1 or more of eyelid redness/eyelid margin redness. 4 Patient who are judged to be needed to administration of azithromycin eye drops for treatment of blepharitis with MGD symptoms. 5 Patients who have all symptoms and findings shown below. Subjective symptoms Abnormal findings around openings of meibomian glands Plugging of meibomian glands 6 Patients who are judged to have symptoms of hypersecretory type MGD.

Exclusion criteria

Exclusion criteria: 1. Patients who understands the contents of the consent document and is able to consent in the document of the person. 2. Age of 20 years or older. 3. Patients who were defined as bacterial blepharitis at the administration start date, and with a score of 1 or more of eyelid redness/eyelid margin redness. 4. Patient who are judged to be needed to administration of azithromycin eye drops for treatment of blepharitis with MGD symptoms. 5. Patients who have all symptoms and findings shown below. Subjective symptoms Abnormal findings around openings of meibomian glands Plugging of meibomian glands 6. Patients who are judged to have symptoms of hypersecretory type MGD. 1. Patients with suspected fungal, viral, or Acanthamoeba. 2. Patients with suspected allergic conjunctivitis. 3. History of recurrent corneal erosion. 4. Any corneal epithelial loss, specifically any corneal ulcer (except for superficial punctate keratitis). 5. Patients who need to use any antibiotic, anti-inflammatory drug, vasoconstrictors, antihistamine, anti-allergic drug, disinfectant, proteolytic enzyme, herbal medicine (systemic topical, or dermally around eyelid), or treatment for MGD symptom (warm compress or lid hygiene) during the study. 6. Patients who will change the therapeutic medication for dry eye during the study. 7. Use of any corticosteroid, nonsteroidal anti-inflammatory drug, immunosuppressant (systemic, topical, or dermally around eyelid) within 1 week of enrollment. 8. Patients use Azimycin 1% eye drops within the past 45 days. 9. History of eye lid surgery within the past 90 days. 10. Known hypersensitivity or adverse effect to azithromycin, other macrolides, or to any of the drug ingredients in the study medications. 11. Participation in any other clinical study within the past 90 days or planning to participation in other clinical studies. 12. In addition, patients who are judged to have a problem to join this study.

Design outcomes

Primary

Measure	Time frame
The total-score variation of subjective and objective findings of blepharitis from baseline at 14th day of administration in subject eye	—

Countries

Japan

Contacts

Public ContactJun Shimazaki

Shimazaki eye clinic/Tokyo Dental College Ichikawa General Hospital Department of Ophthalmology

meishano1@gmail.com03-3580-3518

Outcome results